NCT00004203 - Oxaliplatin in Treating Patients With Metastatic Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2000

Primary Completion Date

February 28, 2002

Study Completion Date

April 30, 2005

Conditions

Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter

Interventions

DRUG

oxaliplatin

Trial Locations (14)

46617

Michiana Hematology/Oncology P.C., South Bend

60068

Division of Hematology/Oncology, Park Ridge

60201

Evanston Northwestern Health Care, Evanston

60612

University of Illinois at Chicago, Chicago

60640

Louis A. Weiss Memorial Hospital, Chicago

61602

Oncology/Hematology Associates of Central Illinois, P.C., Peoria

62526

Cancer Care Specialists of Central Illinois, S.C., Decatur

62701

Central Illinois Hematology Oncology Center, Springfield

60637-1470

University of Chicago Cancer Research Center, Chicago

46885-5099

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

19104-4283

University of Pennsylvania Cancer Center, Philadelphia

L8V 5C2

Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton

N6A 4L6

Cancer Care Ontario-London Regional Cancer Centre, London

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER